A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Clinical trial NCT06977828 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06977828
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)Neoadjuvant Immunotherapy Adjuvant Immunotherapy

Start date: 2025-07-20
Primary completion: 2027-06-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.